AstraZeneca to Acquire Fusion Pharmaceuticals, for Up To $2.4 Billion
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
Stay updated with breaking news from John Valliant. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
By Ben Glickman Shares of Fusion Pharmaceuticals rose in post-market trading on Thursday after the company had a study protocol approved by regulators. The stock was up 7.8% to $9.10,... -January 04, 2024 at 06:39 pm EST - MarketScreener
Fusion reported on Jan. 4 that it has completed validation of its good manufacturing practice (GMP) manufacturing facility and produced the first clinical dose of a TAT.
Aligned with the FDA on submitted protocol for 225Ac-PSMA (FPI-2265) Phase 2/3 registrational program for patients with metastatic castration-resistant...
By Ben Glickman Shares of Fusion Pharmaceuticals rose in post-market trading on Thursday after the company had a study protocol approved by regulators. The...